RSS-Feed abonnieren
DOI: 10.1055/a-2021-0596
Comparison Between Thyroid Stimulating Immunoglobulin and TSH-Receptor Antibodies in the Management of Graves’ Orbitopathy
Funding Open Access funding was provided by Uppsala University. This work was supported by grants from the research of Uppsala University Hospital and the Faculty of Medical Science at Uppsala University.
Abstract
Objectives TSH-receptor antibodies (TRAb) targeting the TSH receptor (TSH-R) induce hyperthyroidism in Graves´ disease (GD). Graves´ orbitopathy (GO) is influenced by stimulation of the TSH-R in the orbita. GO has been, among other factors, linked to high TRAb levels. Thyroid stimulating immunoglobulins (TSI) is a relatively new method for assessing TSH-receptor antibodies. The aim of this study was to investigate the role of TSI in the management of GO.
Methods Patients with newly diagnosed GD (n=30, median age 55 years (range 35–72), 29 women) received pharmacological therapy (methimazole+++thyroxine) for up to 24 months. GO was identified by clinical signs and symptoms. Eleven patients had GO at diagnosis, and another six developed GO during treatment. Blood samples for TSI and other thyroidal biomarkers were obtained at baseline and on five occasions during the 24-month follow-up. Twenty-two subjects completed the drug regimen without surgery or radioiodine treatment.
Results At baseline, TSI was highly correlated with TRAb (r s =0.64, p<0.001), and both assays similarly correlated to fT3 values. TSI and TRAb did not differ significantly between GO and non-GO patients for visit v1 (n=30, 17 GO during the whole study) or at follow-up (n=22, 12 GO during the whole study). During follow-up, levels of TSI and TRAb decreased and normalized in both groups.
Conclusion The present study does not support any added benefit of TSI compared to TRAb for the prediction and management of GO.
Publikationsverlauf
Eingereicht: 13. September 2022
Eingereicht: 22. Dezember 2022
Angenommen: 05. Januar 2023
Accepted Manuscript online:
27. Januar 2023
Artikel online veröffentlicht:
03. März 2023
© 2023. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).
Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany
-
References
- 1 Bahn RS. Autoimmunity and Graves’ disease. Clin Pharmacol Ther 2012; 91: 577-579 DOI: 10.1038/clpt.2012.10.
- 2 Orgiazzi J, Williams DE, Chopra IJ. et al. Human thyroid adenyl cyclase-stimulating activity in immunoglobulin G of patients with Graves’ disease. J Clin Endocrinol Metab 1976; 42: 341-354 DOI: 10.1210/jcem-42-2-341.
- 3 McIver B, Morris JC. The pathogenesis of Graves’ disease. Endocrinol Metab Clin North Am 1998; 27: 73-89 DOI: 10.1016/s0889-8529(05)70299-1.
- 4 Kahaly GJ, Diana T, Olivo PD. TSH receptor antibodies: Relevance & utility. Endocr Pract 2020; 26: 97-106 DOI: 10.4158/EP-2019-0363.
- 5 Lytton SD, Schluter A, Banga PJ. Functional diagnostics for thyrotropin hormone receptor autoantibodies: Bioassays prevail over binding assays. Front Biosci (Landmark Ed) 2018; 23: 2028-2043 DOI: 10.2741/4687.
- 6 Evans M, Sanders J, Tagami T. et al. Monoclonal autoantibodies to the TSH receptor, one with stimulating activity and one with blocking activity, obtained from the same blood sample. Clin Endocrinol (Oxf) 2010; 73: 404-412 DOI: 10.1111/j.1365-2265.2010.03831.x.
- 7 Wiersinga WM, Bartalena L. Epidemiology and prevention of Graves’ ophthalmopathy. Thyroid 2002; 12: 855-860 DOI: 10.1089/105072502761016476.
- 8 Karlsson FA, Dahlberg PA, Jansson R. et al. Importance of TSH receptor activation in the development of severe endocrine ophthalmopathy. Eur J Endocrinol 1989; 121: 132-141
- 9 Bahn RS. Graves’ ophthalmopathy. N Engl J Med 2010; 362: 726-738 DOI: 10.1056/NEJMra0905750.
- 10 Smith TJ. TSHR as a therapeutic target in Graves’ disease. Expert Opin Ther Targets 2017; 21: 427-432 DOI: 10.1080/14728222.2017.1288215.
- 11 Eckstein AK, Plicht M, Lax H. et al. Thyrotropin receptor autoantibodies are independent risk factors for Graves’ ophthalmopathy and help to predict severity and outcome of the disease. J Clin Endocrinol Metab 2006; 91: 3464-3470 DOI: 10.1210/jc.2005-2813.
- 12 Thornton J, Kelly SP, Harrison RA. et al. Cigarette smoking and thyroid eye disease: A systematic review. Eye (Lond) 2007; 21: 1135-1145 DOI: 10.1038/sj.eye.6702603.
- 13 Khoo DH, Ho SC, Seah LL. et al. The combination of absent thyroid peroxidase antibodies and high thyroid-stimulating immunoglobulin levels in Graves’ disease identifies a group at markedly increased risk of ophthalmopathy. Thyroid 1999; 9: 1175-1180 DOI: 10.1089/thy.1999.9.1175.
- 14 Goh SY, Ho SC, Seah LL. et al. Thyroid autoantibody profiles in ophthalmic dominant and thyroid dominant Graves’ disease differ and suggest ophthalmopathy is a multiantigenic disease. Clin Endocrinol (Oxf) 2004; 60: 600-607 DOI: 10.1111/j.1365-2265.2004.02033.x.
- 15 Boyanov MA, Bakalov D, Sheinkova G. Levels of thyroid autoantibodies in patients with Graves’ disease and Graves’ ophtalmopathy Graves Hastal›¤›nda ve Graves Oftalmopatisinde Tiroid Otoantikor Düzeyleri. Turk Jem 2010; 14: 50-53
- 16 Lantz M, Planck T, Asman P. et al. Increased TRAb and/or low anti-TPO titers at diagnosis of graves’ disease are associated with an increased risk of developing ophthalmopathy after onset. Exp Clin Endocrinol Diabetes 2014; 122: 113-117 DOI: 10.1055/s-0033-1363193.
- 17 Mekova RV, Boyanov MA. Clinical, hormonal, and ultrasound characteristics of patients with newly diagnosed Graves’ disease and different thyroid antibody profiles. Acta Medica Bulgarica 2019; 46: 12-15
- 18 Laurberg P, Wallin G, Tallstedt L. et al. TSH-receptor autoimmunity in Graves’ disease after therapy with anti-thyroid drugs, surgery, or radioiodine: A 5-year prospective randomized study. Eur J Endocrinol 2008; 158: 69-75 DOI: 10.1530/EJE-07-0450.
- 19 Smith TJ, Hegedus L. Graves’ disease. N Engl J Med 2016; 375: 1552-1565 DOI: 10.1056/NEJMra1510030.
- 20 Bartalena L. Diagnosis and management of Graves disease: A global overview. Nat Rev Endocrinol 2013; 9: 724-734 DOI: 10.1038/nrendo.2013.193.
- 21 Stohr M, Oeverhaus M, Lytton SD. et al. Predicting the relapse of hyperthyroidism in treated Graves’ disease with orbitopathy by serial measurements of TSH-receptor autoantibodies. Horm Metab Res 2021; 53: 235-244 DOI: 10.1055/a-1373-5523.
- 22 Frank CU, Braeth S, Dietrich JW. et al. Bridge technology with TSH receptor chimera for sensitive direct detection of TSH receptor antibodies causing Graves’ disease: Analytical and clinical evaluation. Horm Metab Res 2015; 47: 880-888 DOI: 10.1055/s-0035-1554662.
- 23 Tozzoli R, D’Aurizio F, Villalta D. et al. Evaluation of the first fully automated immunoassay method for the measurement of stimulating TSH receptor autoantibodies in Graves’ disease. Clin Chem Lab Med 2017; 55: 58-64 DOI: 10.1515/cclm-2016-0197.
- 24 Hu Y, Ni J, Cen Y. et al. Evaluation of analytic and clinical performance of two immunoassays for detecting thyroid-stimulating receptor antibody in the diagnosis of Graves’ disease. J Clin Lab Anal 2021; 35: e23950 DOI: 10.1002/jcla.23950.
- 25 Irawati Y, Juhrie DM, Paramita C. et al. Sight-threatening condition in severe thyroid eye disease: How we should manage. Acta Med Indones 2022; 54: 124-130
- 26 Jang SY, Shin DY, Lee EJ. et al. Relevance of TSH-receptor antibody levels in predicting disease course in Graves’ orbitopathy: Comparison of the third-generation TBII assay and Mc4-TSI bioassay. Eye (Lond) 2013; 27: 964-971 DOI: 10.1038/eye.2013.120.
- 27 Khamisi S, Lundqvist M, Emadi P. et al. Serum thyroglobulin is associated with orbitopathy in Graves’ disease. J Endocrinol Invest 2021; 44: 1905-1911 DOI: 10.1007/s40618-021-01505-8.
- 28 Bartalena L, Kahaly GJ, Baldeschi L. et al. The 2021 European Group on Graves’ orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves’ orbitopathy. Eur J Endocrinol 2021; 185: G43-G67 DOI: 10.1530/EJE-21-0479.
- 29 Giuliani C, Cerrone D, Harii N. et al. A TSHR-LH/CGR chimera that measures functional thyroid-stimulating autoantibodies (TSAb) can predict remission or recurrence in Graves’ patients undergoing antithyroid drug (ATD) treatment. J Clin Endocrinol Metab 2012; 97: E1080-E1087 DOI: 10.1210/jc.2011-2897.
- 30 Bahn RS. TSH receptor expression in orbital tissue and its role in the pathogenesis of Graves’ ophthalmopathy. J Endocrinol Invest 2004; 27: 216-220 DOI: 10.1007/BF03345269.
- 31 Araki N, Iida M, Amino N. et al. Rapid bioassay for detection of thyroid-stimulating antibodies using cyclic adenosine monophosphate-gated calcium channel and aequorin. Eur Thyroid J 2015; 4: 14-19 DOI: 10.1159/000371740.
- 32 D’Aurizio F. The role of laboratory medicine in the diagnosis of the hyperthyroidism. Q J Nucl Med Mol Imaging 2021; 65: 91-101 DOI: 10.23736/S1824-4785.21.03344-6.
- 33 Tozzoli R. The increasing clinical relevance of thyroid-stimulating hormone receptor autoantibodies and the concurrent evolution of assay methods in autoimmune hyperthyroidism. J Lab Precis Med 2018; 3: 27
- 34 Thia B, McGuinness MB, Ebeling PR. et al. Diagnostic accuracy of Immulite(R) TSI immunoassay for thyroid-associated orbitopathy in patients with recently diagnosed Graves’ hyperthyroidism. Int Ophthalmol 2022; 42: 863-870 DOI: 10.1007/s10792-021-02052-0.
- 35 Bluszcz GA, Bednarczuk T, Bartoszewicz Z. et al. Clinical utility of TSH receptor antibody levels in Graves’ orbitopathy: A comparison of two TSH receptor antibody immunoassays. Cent Eur J Immunol 2018; 43: 405-412 DOI: 10.5114/ceji.2018.80224.